Transdermal lovastatin enhances fracture repair in rats.

Statins have been shown to stimulate BMP2 transcription and bone formation. This raises the possibility that they could be useful for enhancing rates of fracture repair. Observational studies in patients treated with oral statins for lipid-lowering have been controversial. The likely reason for thei...

Full description

Bibliographic Details
Main Authors: Gutierrez, G, Edwards, J, Garrett, I, Nyman, J, McCluskey, B, Rossini, G, Flores, A, Neidre, D, Mundy, G
Format: Journal article
Language:English
Published: 2008
_version_ 1797057208673894400
author Gutierrez, G
Edwards, J
Garrett, I
Nyman, J
McCluskey, B
Rossini, G
Flores, A
Neidre, D
Mundy, G
author_facet Gutierrez, G
Edwards, J
Garrett, I
Nyman, J
McCluskey, B
Rossini, G
Flores, A
Neidre, D
Mundy, G
author_sort Gutierrez, G
collection OXFORD
description Statins have been shown to stimulate BMP2 transcription and bone formation. This raises the possibility that they could be useful for enhancing rates of fracture repair. Observational studies in patients treated with oral statins for lipid-lowering have been controversial. The likely reason for their inconsistent effects is that the statin concentration reaching the periphery was too low after oral administration to produce a reproducible biologic effect. Thus, we examined the effects of lovastatin (LV) given transdermally in a well-described preclinical model of fracture repair. Effects on the healing fracture callus were assessed by biomechanical strength, radiographs, and quantitative morphology. LV was administered transdermally (TD) for 5 days after fracture in several doses (0.1-5 mg/kg/d) and compared with vehicle-treated control rats and rats treated with LV by oral gavage (PO) at 5-25 mg/kg/d for 5 days from the day of fracture. Radiological evaluation of bones treated with TD LV showed enhanced fracture repair at 2 and 6 wk. BMD in the callus area at 6 wk was also increased in the TD group compared with vehicle-treated controls (p < 0.05). The force required to break TD-treated bones (0.1 mg/kg/d for 5 days) was 42% greater than vehicle-treated controls (p < 0.02), and there was a 90% increase in stiffness (p < 0.01). PO LV at much higher doses (10 and 25 mg/kg/d) showed increased stiffness but no change in other biomechanical properties. By histological examination, a significant increase was also observed in the size of the callus, surrounding proliferating cell nuclear antigen-positive cells, and osteoblast and osteoclast number in TD-treated rats compared with controls at day 8 after fracture (n = 6). In summary, we found that TD LV in low doses accelerates fracture healing, whereas 10-fold the lipid-lowering dose was required to produce any effect when it was administered orally. These studies provide valuable information on the potential of statins and TD delivery as a new and effective therapeutic modality in fracture repair.
first_indexed 2024-03-06T19:33:00Z
format Journal article
id oxford-uuid:1e1c28fe-3a7d-4f67-acc7-636e3e0a29f9
institution University of Oxford
language English
last_indexed 2024-03-06T19:33:00Z
publishDate 2008
record_format dspace
spelling oxford-uuid:1e1c28fe-3a7d-4f67-acc7-636e3e0a29f92022-03-26T11:14:33ZTransdermal lovastatin enhances fracture repair in rats.Journal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:1e1c28fe-3a7d-4f67-acc7-636e3e0a29f9EnglishSymplectic Elements at Oxford2008Gutierrez, GEdwards, JGarrett, INyman, JMcCluskey, BRossini, GFlores, ANeidre, DMundy, GStatins have been shown to stimulate BMP2 transcription and bone formation. This raises the possibility that they could be useful for enhancing rates of fracture repair. Observational studies in patients treated with oral statins for lipid-lowering have been controversial. The likely reason for their inconsistent effects is that the statin concentration reaching the periphery was too low after oral administration to produce a reproducible biologic effect. Thus, we examined the effects of lovastatin (LV) given transdermally in a well-described preclinical model of fracture repair. Effects on the healing fracture callus were assessed by biomechanical strength, radiographs, and quantitative morphology. LV was administered transdermally (TD) for 5 days after fracture in several doses (0.1-5 mg/kg/d) and compared with vehicle-treated control rats and rats treated with LV by oral gavage (PO) at 5-25 mg/kg/d for 5 days from the day of fracture. Radiological evaluation of bones treated with TD LV showed enhanced fracture repair at 2 and 6 wk. BMD in the callus area at 6 wk was also increased in the TD group compared with vehicle-treated controls (p < 0.05). The force required to break TD-treated bones (0.1 mg/kg/d for 5 days) was 42% greater than vehicle-treated controls (p < 0.02), and there was a 90% increase in stiffness (p < 0.01). PO LV at much higher doses (10 and 25 mg/kg/d) showed increased stiffness but no change in other biomechanical properties. By histological examination, a significant increase was also observed in the size of the callus, surrounding proliferating cell nuclear antigen-positive cells, and osteoblast and osteoclast number in TD-treated rats compared with controls at day 8 after fracture (n = 6). In summary, we found that TD LV in low doses accelerates fracture healing, whereas 10-fold the lipid-lowering dose was required to produce any effect when it was administered orally. These studies provide valuable information on the potential of statins and TD delivery as a new and effective therapeutic modality in fracture repair.
spellingShingle Gutierrez, G
Edwards, J
Garrett, I
Nyman, J
McCluskey, B
Rossini, G
Flores, A
Neidre, D
Mundy, G
Transdermal lovastatin enhances fracture repair in rats.
title Transdermal lovastatin enhances fracture repair in rats.
title_full Transdermal lovastatin enhances fracture repair in rats.
title_fullStr Transdermal lovastatin enhances fracture repair in rats.
title_full_unstemmed Transdermal lovastatin enhances fracture repair in rats.
title_short Transdermal lovastatin enhances fracture repair in rats.
title_sort transdermal lovastatin enhances fracture repair in rats
work_keys_str_mv AT gutierrezg transdermallovastatinenhancesfracturerepairinrats
AT edwardsj transdermallovastatinenhancesfracturerepairinrats
AT garretti transdermallovastatinenhancesfracturerepairinrats
AT nymanj transdermallovastatinenhancesfracturerepairinrats
AT mccluskeyb transdermallovastatinenhancesfracturerepairinrats
AT rossinig transdermallovastatinenhancesfracturerepairinrats
AT floresa transdermallovastatinenhancesfracturerepairinrats
AT neidred transdermallovastatinenhancesfracturerepairinrats
AT mundyg transdermallovastatinenhancesfracturerepairinrats